Rheumatology · Clinical trials
Psoriatic Arthritis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About psoriatic arthritis — and why its trials are hard
Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis associated with psoriasis, encompassing peripheral arthritis, enthesitis, dactylitis, axial disease, and nail and skin involvement. Management has advanced from conventional DMARDs like methotrexate to a broad biologic and targeted-synthetic armamentarium. TNF inhibitors (e.g., adalimumab) were the first biologics to show major joint benefit. Interleukin-17A inhibitors (secukinumab, ixekizumab) and the interleukin-12/23 inhibitor ustekinumab followed, then the more selective interleukin-23 (p19) inhibitor guselkumab, and oral JAK inhibitors (tofacitinib, upadacitinib). The apremilast PDE4 inhibitor provides an oral non-biologic option. The core regulatory efficacy endpoint is ACR20 (a composite 20% improvement) at around week 16-24, supplemented by skin (PASI), enthesitis, dactylitis, and structural progression measures. Drug selection is increasingly tailored to dominant domains and comorbidities. The field also illustrates domain- and safety-specific limits: brodalumab's PsA program was halted over a psychiatric safety signal, and interleukin-6 blockade proved disappointing, reminding clinicians that psoriasis efficacy does not guarantee joint efficacy or acceptable safety.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Adalimumab (Humira) | 2005 | Active PsA; TNF inhibitor | ADEPT | ACR20 at week 12/24 | ~57-58% vs ~14-15% placebo |
| Ustekinumab (Stelara) | 2013 | Active PsA; IL-12/23 (p40) inhibitor | PSUMMIT 1 and PSUMMIT 2 | ACR20 at week 24 | ~42-50% vs ~23% placebo |
| Secukinumab (Cosentyx) | 2016 | Active PsA; IL-17A inhibitor | FUTURE 2 | ACR20 at week 24 | ~54% (300 mg) vs ~15% placebo |
| Ixekizumab (Taltz) | 2017 | Active PsA; IL-17A inhibitor | SPIRIT-P1 | ACR20 at week 24 | ~58-62% vs ~30% placebo |
| Guselkumab (Tremfya) | 2020 | Active PsA; IL-23 (p19) inhibitor | DISCOVER-2 (biologic-naive) | ACR20 at week 24 | ~64% vs ~33% placebo |
| Upadacitinib (Rinvoq) | 2021 | Active PsA; oral JAK inhibitor | SELECT-PsA 1 | ACR20 at week 12 | ~71% vs ~36% placebo |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in psoriatic arthritis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Brodalumab — AMVISION-1 and AMVISION-2 (IL-17 receptor A inhibitor) | PsA program suspended in 2015 despite efficacy; development in PsA was not completed | A suicidal ideation and behavior safety signal in the psoriasis program led the sponsor to halt broader development in PsA |
| Clazakizumab — Phase 2b PsA study (anti-IL-6 monoclonal antibody) | Showed only limited joint benefit and was not advanced into phase 3 for PsA | IL-6 blockade proved a poor target in psoriatic disease, with modest ACR responses and no meaningful skin benefit (exact magnitudes unverified) |
Choosing the right endpoint
Primary endpoints that matter in psoriatic arthritis trials
- ACR20/50/70 — Composite response (20/50/70% improvement) in joints and other measures; ACR20 is the standard primary endpoint.
- PASI 75/90 — Skin clearance measure important given concomitant psoriasis; IL-17 and IL-23 agents excel here.
- Enthesitis and dactylitis resolution — Domain-specific endpoints (e.g., LEI, dactylitis count) reflecting characteristic PsA features.
- Radiographic progression (mTSS) — Structural damage inhibition, demonstrated for TNF, IL-17, IL-23, and JAK agents.
How iNGENū runs psoriatic arthritis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Psoriatic Arthritis clinical trials — FAQs
Is ACR20 the main approval endpoint in PsA?
Do IL-23 inhibitors work in PsA?
Why did brodalumab not reach the PsA market?
Ready to discuss your psoriatic arthritis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal